Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

BACKGROUND: Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti‐angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects. Therefore, we...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Commun (Lond)
Hlavní autoři: Zhang, Bo, Qi, Ling, Wang, Xi, Xu, Jianping, Liu, Yun, Mu, Lan, Wang, Xingyuan, Bai, Lidan, Huang, Jing
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7743020/
https://ncbi.nlm.nih.gov/pubmed/33314747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12119
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky